Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
Treatment of relapsed/refractory multiple myeloma (RRMM) is more complex today due to the availability of novel therapeutic options, mostly applied as combination regimens. immunotherapy options have especially increased substantially, likewise the understanding that patient-, disease- and treatment...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/17/4320 |
id |
doaj-5abb713854784e3a880691b8fa257138 |
---|---|
record_format |
Article |
spelling |
doaj-5abb713854784e3a880691b8fa2571382021-09-09T13:40:28ZengMDPI AGCancers2072-66942021-08-01134320432010.3390/cancers13174320Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related FactorsLaura Gengenbach0Giulia Graziani1Heike Reinhardt2Amelie Rösner3Magdalena Braun4Mandy-Deborah Möller5Christine Greil6Ralph Wäsch7Monika Engelhardt8University Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyUniversity Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyUniversity Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyUniversity Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyUniversity Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyUniversity Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyUniversity Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyUniversity Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyUniversity Medical Center Freiburg, Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, GermanyTreatment of relapsed/refractory multiple myeloma (RRMM) is more complex today due to the availability of novel therapeutic options, mostly applied as combination regimens. immunotherapy options have especially increased substantially, likewise the understanding that patient-, disease- and treatment-related factors should be considered at all stages of the disease. RRMM is based on definitions of the international myeloma working group (IMWG) and includes biochemical progression, such as paraprotein increase, or symptomatic relapse with CRAB criteria (hypercalcemia, renal impairment, anemia, bone lesions). When choosing RRMM-treatment, the biochemical markers for progression and severity of the disease, dynamic of disease relapse, type and number of prior therapy lines, including toxicity and underlying health status, need to be considered, and shared decision making should be pursued. Objectively characterizing health status via geriatric assessment (GA) at each multiple myeloma (MM) treatment decision point has been shown to be a better estimate than via age and comorbidities alone. The well-established national comprehensive cancer network, IMWG, European myeloma network and other national treatment algorithms consider these issues. Ideally, GA-based clinical trials should be supported in the future to choose wisely and efficaciously from available intervention and treatment options in often-older MM adults in order to further improve morbidity and mortality.https://www.mdpi.com/2072-6694/13/17/4320relapsed/refractory multiple myeloma (RRMM)novel agentsimmunotherapyfrailtygeriatric assessment (GA)revised myeloma comorbidity Index (R-MCI) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laura Gengenbach Giulia Graziani Heike Reinhardt Amelie Rösner Magdalena Braun Mandy-Deborah Möller Christine Greil Ralph Wäsch Monika Engelhardt |
spellingShingle |
Laura Gengenbach Giulia Graziani Heike Reinhardt Amelie Rösner Magdalena Braun Mandy-Deborah Möller Christine Greil Ralph Wäsch Monika Engelhardt Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors Cancers relapsed/refractory multiple myeloma (RRMM) novel agents immunotherapy frailty geriatric assessment (GA) revised myeloma comorbidity Index (R-MCI) |
author_facet |
Laura Gengenbach Giulia Graziani Heike Reinhardt Amelie Rösner Magdalena Braun Mandy-Deborah Möller Christine Greil Ralph Wäsch Monika Engelhardt |
author_sort |
Laura Gengenbach |
title |
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors |
title_short |
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors |
title_full |
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors |
title_fullStr |
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors |
title_full_unstemmed |
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors |
title_sort |
choosing the right therapy for patients with relapsed/refractory multiple myeloma (rrmm) in consideration of patient-, disease- and treatment-related factors |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-08-01 |
description |
Treatment of relapsed/refractory multiple myeloma (RRMM) is more complex today due to the availability of novel therapeutic options, mostly applied as combination regimens. immunotherapy options have especially increased substantially, likewise the understanding that patient-, disease- and treatment-related factors should be considered at all stages of the disease. RRMM is based on definitions of the international myeloma working group (IMWG) and includes biochemical progression, such as paraprotein increase, or symptomatic relapse with CRAB criteria (hypercalcemia, renal impairment, anemia, bone lesions). When choosing RRMM-treatment, the biochemical markers for progression and severity of the disease, dynamic of disease relapse, type and number of prior therapy lines, including toxicity and underlying health status, need to be considered, and shared decision making should be pursued. Objectively characterizing health status via geriatric assessment (GA) at each multiple myeloma (MM) treatment decision point has been shown to be a better estimate than via age and comorbidities alone. The well-established national comprehensive cancer network, IMWG, European myeloma network and other national treatment algorithms consider these issues. Ideally, GA-based clinical trials should be supported in the future to choose wisely and efficaciously from available intervention and treatment options in often-older MM adults in order to further improve morbidity and mortality. |
topic |
relapsed/refractory multiple myeloma (RRMM) novel agents immunotherapy frailty geriatric assessment (GA) revised myeloma comorbidity Index (R-MCI) |
url |
https://www.mdpi.com/2072-6694/13/17/4320 |
work_keys_str_mv |
AT lauragengenbach choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors AT giuliagraziani choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors AT heikereinhardt choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors AT amelierosner choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors AT magdalenabraun choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors AT mandydeborahmoller choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors AT christinegreil choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors AT ralphwasch choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors AT monikaengelhardt choosingtherighttherapyforpatientswithrelapsedrefractorymultiplemyelomarrmminconsiderationofpatientdiseaseandtreatmentrelatedfactors |
_version_ |
1717760731455160320 |